Dr. Harding on the Management of Immune-related AEs in Advanced Biliary Tract Cancer
James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.
Dr. Harding on Future Directions in the Treatment of Advanced Biliary Tract Cancers
James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.
Dr. Harding on the Evolution of Frontline Chemotherapy Approaches in Advanced Biliary Tract Cancer
James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.
Dr. Harding on the Prevalence of TSC1/2 Mutations in GI Cancer
James J. Harding, MD, discusses the prevalence of TSC1 and TSC2 mutations in gastrointestinal cancer, and the need to develop a standard-of-care treatment for patients with these genetic alterations.
Dr. Harding on the Results of the SUMMIT Trial in HER2+ Biliary Tract Cancers
James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.
Dr. Harding on Exciting Research Efforts in the Pipeline for HCC
James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.
Dr. Harding on the Goal of the IMbrave150 trial in HCC
James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512